eISSN : 2146-9369
Creative Commons Lisansı
Journal of Clinical and Experimental Investigations is licenced under the terms of Creative Commons Attribution-Non Commercial4.0 International (CC BY-NC 4.0) License.
Abstract - The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin
Hayati Demiraslan, Zeynep Ture, Aysegul Ulu Kılıc

 

The pegylated interferon alpha and ribavirin treatment is well established therapy for hepatitis C virus (HCV) infection. 
During the treatment alanine aminotransferase (ALT) lare may be observed rarely.
A 51-year-old female receiving pegylated interferon and ribavirin therapy for HCV infection, complained nausea, vomit-
ing in seventh week of the therapy, and her ALT level was detected over 20 times above the normal level. Hepatitis B sur-
face antigen, anti-nuclear antibody, anti-mitochondrial antibody, anti-double stranded DNA antibody and anti-hepatitis 
A virus IgM antibody were negative, and thyroid stimulating hormone was normal. HCV RNA level was 424 IU/ml. PEG 
IFN and ribavirin therapy was interrupted for three weeks, after liver enzyme level was detected less than 100U/L, the 
treatment was resumed. The patient was followed up for 2 months, ALT lare was not observed.
In  conclusion, we present  a  rare  case with ALT  lare, while  receiving pegylated  interferon  and  ribavirin  therapy  for 
chronic HCV infection. J Microbiol Infect Dis 2012; 2(3): 121-123
Volume 02, Number 03 (2012)